Adocia S.A. is a biopharmaceutical company dedicated to the development of innovative insulin formulations to improve the treatment of diabetes. The company's primary focus is on enhancing the delivery and effectiveness of insulin therapies for both Type 1 and Type 2 diabetes, addressing a vital sector in the healthcare industry. Leveraging its proprietary BioChaperone technology platform, Adocia aims to optimize insulin kinetics, thereby improving patient outcomes and experiences. This platform enables the formulation of insulin analogues that offer faster onset times and reduced injection frequency, potentially transforming standard treatment protocols. Headquartered in Lyon, France, Adocia collaborates with leading pharmaceutical companies to advance its pipeline of promising therapeutics. By emphasizing innovation in diabetes care, Adocia plays a significant role in the ongoing global effort to address the growing prevalence of metabolic disorders and enhance the quality of life for millions of patients worldwide.